Boston Partners Trims Position in Johnson & Johnson (NYSE:JNJ)

Posted by on May 12th, 2023

Boston Partners reduced its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,674,076 shares of the company’s stock after selling 366,795 shares during the quarter. Johnson & Johnson accounts for 2.1% of Boston Partners’ portfolio, making the stock its largest position. Boston Partners owned approximately 0.33% of Johnson & Johnson worth $1,528,197,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in JNJ. Veracity Capital LLC lifted its stake in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after purchasing an additional 59 shares during the last quarter. Sandy Cove Advisors LLC lifted its stake in Johnson & Johnson by 1.6% in the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after purchasing an additional 60 shares during the last quarter. LCM Capital Management Inc lifted its stake in Johnson & Johnson by 0.7% in the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC lifted its stake in Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Finally, Magnolia Capital Advisors LLC lifted its stake in Johnson & Johnson by 0.7% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock valued at $1,451,000 after purchasing an additional 62 shares during the last quarter. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.4 %

Shares of NYSE JNJ opened at $160.99 on Friday. The stock has a market capitalization of $418.37 billion, a P/E ratio of 33.68, a P/E/G ratio of 2.77 and a beta of 0.53. The company has a 50-day moving average price of $158.97 and a 200-day moving average price of $166.83. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the company earned $2.67 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.96%. Johnson & Johnson’s payout ratio is 94.56%.

Wall Street Analyst Weigh In

Several brokerages recently commented on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Piper Sandler dropped their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Finally, UBS Group initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $173.00.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.